Health Affairs, 25, no. 2 (2006): 452-460 doi: 10.1377/hlthaff.25.2.452 © 2006 by Project HOPE	New Online   New Issue: China & India   Obesity In China   Pay Cuts For Medicare Docs   Access To Care Woes

This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Grabowski, H. G. Articles by Wang, Y. R. Search for Related Content PubMed PubMed Citation Articles by Grabowski, H. G. Articles by Wang, Y. R. Related Collections Business Of Health International Issues Legal/Regulatory Issues Pharmaceuticals Research And Technology

Health Tracking

TRENDS

The Quantity And Quality Of Worldwide New Drug Introductions, 1982–2003

We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over time, introductions of high-quality NCEs (that is, global and first-in-class NCEs) increased moderately. Both biotech and orphan products enjoyed tremendous growth, especially for cancer treatment. Country-level analyses for 1993–2003 indicate that U.S. firms overtook their European counterparts in innovative performance or the introduction of first-in-class, biotech, and orphan products. The United States also became the leading market for first launch.

                      What's this?

This article has been cited by other articles:

				J. A. DiMasi and H. G. Grabowski Economics of New Oncology Drug Development J. Clin. Oncol., January 10, 2007; 25(2): 209 - 216. [Abstract] [Full Text] [PDF]

				D. B. Ridley, J. M. Kramer, H. H. Tilson, H. G. Grabowski, and K. A. Schulman Spending on postapproval drug safety. Health Aff., March 1, 2006; 25(2): 429 - 436. [Abstract] [Full Text] [PDF]